



## C4 Therapeutics Appoints Andrew Phillips, Ph.D. as President and Chief Scientific Officer

September 14, 2016 11:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--[C4 Therapeutics](#) (C4T) today announced that Andrew Phillips, Ph.D. has been promoted to President and Chief Scientific Officer, reporting directly to Executive Chairman Marc Cohen. The Company also announced that Jason Fisherman, M.D. has resigned as President/CEO and as a member of the Board of Directors to pursue other professional opportunities. Since joining C4T as Chief Scientific Officer in January 2016, Dr. Phillips has been leading the development of Targeted Protein Degradation (TPD) therapeutics based on the Company's groundbreaking Degronimid™ platform.

"Andy has played a key role in C4T's rapid growth since joining us earlier this year. He has been instrumental in the recruitment of world-class scientific talent, the development of a robust internal drug discovery portfolio, and the initiation of our strategic alliance with Roche. C4T is a science-driven company and Andy is ideally suited to lead the Company in the development of therapeutics in his expanded role as President and Chief Scientific Officer," said Marc Cohen, Co-Founder and Executive Chairman of C4 Therapeutics. "We thank Jason for his leadership and contribution to the C4T launch and wish him the best as he pursues other endeavors."

Prior to joining C4T, Dr. Phillips was Senior Director, Center for Development of Therapeutics at the Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships. Previously, he was a Full Professor of Chemistry at Yale University, where he received the ACS Cope Scholar Award for his research accomplishments, which included the development of small molecules aimed at modulating 'undruggable' targets. Prior to this, he was a Full Professor of Chemistry and Biochemistry at the University of Colorado at Boulder, where his efforts in complex molecule synthesis and targeting protein-protein interactions garnered a number of awards, including an Alfred P. Sloan Research Fellowship, an Eli Lilly Grantee Award, and a National Science Foundation CAREER Award.

Dr. Phillips received a B.Sc. (Hons) in biochemistry and a Ph.D. in biochemistry and chemistry from the University of Canterbury in New Zealand and completed a postdoctoral fellowship in organic chemistry at the University of Pittsburgh.

### About C4 Therapeutics

C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T's Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T's internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.

More information about C4 Therapeutics is available at [www.C4Therapeutics.com](http://www.C4Therapeutics.com).

### Contacts

#### Media:

MacDougall Biomedical Communications  
Kari Watson or Casey R. Doucette, Ph.D., 781-235-3060  
[cdoucette@macbiocom.com](mailto:cdoucette@macbiocom.com)